Promising experimental drug could shield nerve cells from amyotrophic lateral sclerosis damage
· Medical Xpressedited by Stephanie Baum, reviewed by Robert Egan
Stephanie Baum
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Amyotrophic lateral sclerosis (ALS) received widespread attention in the summer of 2014 thanks to the Ice Bucket Challenge. Millions of people participated, drenching themselves in ice-cold water to raise awareness of this devastating neurodegenerative disease and generate charitable donations for research. The challenge takes place every year, but ALS still has no known treatment or cure.
Now, University of Arizona researchers have found a promising experimental drug that could shield nerve cells from ALS damage. Working in mice and in human nerve cells in the brain and spinal cord, the researchers found that blocking a small part of a key protein involved in ALS protects the nerve cells the disease damages. Their study is published in Nature Aging.
"Current FDA-approved treatments for ALS provide only modest benefits. There is an urgent need for a real breakthrough," said Xinglong Wang, senior author of the paper and a professor at the R. Ken Coit College of Pharmacy. Wang published the study along with first author Dr. Ju Gao, an assistant research professor at the Coit College of Pharmacy.
A common protein at the center
ALS is difficult to treat because it is often diagnosed only after substantial nerve cell damage has already occurred. The first sign is often weakness in a leg or an arm, Wang said, but by the time symptoms appear, much of the damage is already done.
For most patients, the cause of ALS is a mystery. Fewer than one in 10 cases are inherited through a known genetic mutation. The rest, more than 90%, arise sporadically with no family history and no clear genetic cause. However, nearly all cases share one thing in common: A protein called TDP-43 clumps abnormally inside nerve cells, whether the disease is inherited or not. That clumping is now commonly used to confirm the diagnosis at autopsy.
TDP-43 is not a foreign or defective protein, but one that nearly all cells normally make and need to function. In ALS, TDP-43, which usually resides in the brain's nerve cells, drifts out of the cells and forms toxic clumps. Several theories point to possible drug targets to clear the clumps, but none have led to an effective treatment. Wang's team took a different approach by looking directly at the protein itself.
"We asked a simple question that had never been tested: Is there one specific part of TDP-43 that's causing the harm, something a drug could switch off without disturbing the rest?" Wang said.
Pinpointing the harmful region
The team found a small region in the protein that was nearly identical across species, from mice to humans, with many disease-causing mutations clustering there. When they deleted this region in mice, the nerve cell death caused by TDP-43 dropped sharply. Removing it also left the protein's normal function intact.
Wang said the work took a decade, with much of it spent confirming that the deletion did not disturb healthy function or cause side effects.
After rigorous testing, Wang's team narrowed in on an experimental drug, XL20, which could latch onto the target region in the TDP-43 protein. Most importantly, the drug could cross the blood–brain barrier, the filter that keeps most drugs out of the brain.
In mice, the experimental drug extended median survival by about a week, a meaningful gain over the short life span of mice. XL20 also protected nerve cells and reduced muscle weakness. In the lab, the team also tested XL20 on human motor neurons, the specialized nerve cells in the brain and spinal cord, where it reversed some of the same damage.
Potential beyond ALS
Because XL20 targets TDP-43 directly and already works in human nerve cells, Wang said it represents a promising candidate for future clinical development. Also, because ALS typically develops over months to years after symptoms first appear, Wang said earlier treatment could offer a greater opportunity to slow disease progression.
The study's findings may reach well beyond ALS, Wang said. The same TDP-43 pathology (abnormality) is central to a common age-related dementia called LATE (limbic-predominant age-related TDP-43 encephalopathy), which affects roughly 1 in 3 people over 80. TDP-43 pathology is also found in more than half of Alzheimer's patients and is associated with faster cognitive decline.
"The same TDP-43 pathology is implicated in several other neurodegenerative diseases," Wang said. "If future studies show this approach works in those diseases as well, it could eventually benefit a much larger patient population."
Publication details
Therapeutic targeting of the conserved region within the low-complexity domain of TDP-43 is neuroprotective and extends survival in amyotrophic lateral sclerosis mice, Nature Aging (2026). DOI: 10.1038/s43587-026-01166-3
Journal information: Nature Aging
Key medical concepts
Clinical categories
NeurologyClinical pharmacology Provided by University of Arizona Who's behind this story?
Stephanie Baum
Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Promising experimental drug could shield nerve cells from amyotrophic lateral sclerosis damage (2026, July 3) retrieved 3 July 2026 from https://medicalxpress.com/news/2026-07-experimental-drug-shield-nerve-cells.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.